Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
232120
Sigma-AldrichCisplatin - CAS 15663-27-1 - Calbiochem
Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.
More>>Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation. Less<<
Cisplatin - CAS 15663-27-1 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
A platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation. Reported to sensitize glioma cells to TNF-α-induced apoptosis.
Note: Athough highly soluble in DMSO, Cisplatin is reported to be rendered inactive due to ligand displacement by the nucleophilic sulfur of DMSO. Sodium chloride solution in water (154 mM NaCl with or without 10 mg/ml mannitol) or PBS (with 140 mM NaCl) is recommended for solubilization prior to culture treatment.
Catalogue Number
232120
Brand Family
Calbiochem®
Synonyms
CPDC, DDP, cis-Diaminedichloroplatinum
References
References
Hall, M.D., et al. 2014. Cancer Res. In press. Duan, L., et al. 2001. J. Neurooncol.52, 23. Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241. Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.
Toxic if swallowed. Irritating to eyes, respiratory system and skin. May cause cancer. May cause sensitization by inhalation and skin contact.
S Phrase
S: 22-24-37-45-53
Do not breathe dust. Avoid contact with skin. Wear suitable gloves. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Avoid exposure - obtain special instructions before use.
Product Usage Statements
Storage and Shipping Information
Ship Code
Ambient Temperature Only
Toxicity
Toxic & Carcinogenic / Teratogenic
Hazardous Materials Attention:
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Storage
+2°C to +8°C
Do not freeze
Ok to freeze
Special Instructions
Unstable in solution; reconstitute just prior to use.
Cisplatin - CAS 15663-27-1 - Calbiochem Certificates of Analysis
Title
Lot Number
232120
References
Reference overview
Hall, M.D., et al. 2014. Cancer Res. In press. Duan, L., et al. 2001. J. Neurooncol.52, 23. Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241. Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
08-July-2014 JSW
Synonyms
CPDC, DDP, cis-Diaminedichloroplatinum
Description
A platinum coordination complex with potent antineoplastic activity.
Note: Athough highly soluble in DMSO, Cisplatin is reported to be rendered inactive due to ligand displacement by the nucleophilic sulfur of DMSO. Sodium chloride solution in water (154 mM NaCl with or without 10 mg/ml mannitol) or PBS (with 140 mM NaCl) is recommended for solubilization prior to culture treatment.
Form
Yellow solid
CAS number
15663-27-1
RTECS
TP2450000
Chemical formula
Pt(NH₃)₂Cl₂
Structure formula
Purity
≥98% by HPLC
Solubility
DMSO (10 mg/ml), H₂O with 154 mM NaCl (1 mg/ml), or PBS with 140 mM NaCl (1 mg/ml)
Storage
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Unstable in solution; reconstitute just prior to use.
Toxicity
Toxic & Carcinogenic / Teratogenic
Merck USA index
14, 2317
References
Hall, M.D., et al. 2014. Cancer Res. In press. Duan, L., et al. 2001. J. Neurooncol.52, 23. Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241. Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.